Revocation of Two Authorizations of Emergency Use of In Vitro Diagnostic Devices for Detection and/or Diagnosis of COVID-19; Availability, 91760-91763 [2024-27094]
Download as PDF
khammond on DSK9W7S144PROD with NOTICES
91760
Federal Register / Vol. 89, No. 224 / Wednesday, November 20, 2024 / Notices
the persons as legitimate subjects in the
CDAD clinical trial, when in fact they
were not. Mr. Montalvo Villa was
primarily responsible for completing the
patients’ informed consent form and
falsifying their signatures to make it
appear as though the patients consented
to participate in the clinical trial when
they had not. In addition, Mr. Montalvo
Villa along with his co-conspirators
submitted his own stool and blood
samples to make it appear as if they
came from study participants.
Furthermore, Mr. Montalvo Villa was
one of only two individuals who
inputted CDAD clinical trial data in the
Almac Clinical Technology Integrated
Response Technology database (Almac
database). The information in the Almac
database was the foundation for all
subsequent subject CDAD clinical trial
data. Mr. Montalvo Villa repeatedly
entered false and fabricated subject
screening and randomization
information in the Almac database.
After an on-site audit by the Sponsor
of AMB, the Sponsor notified the FDA
in writing of potential scientific
misconduct by AMB. Mr. Montalvo
Villa wrote AMB’s response letter,
which contained false information, for
the Principal Investigator’s signature.
Mr. Montalvo Villa told the Principal
Investigator that she would lose her
medical license if she did not sign the
letter. In addition, an FDA regulatory
investigator conducted an official onsite inspection of AMB for the CDAD
clinical trial that began on February 20,
2018. On the first day of the inspection,
Mr. Montalvo Villa told the FDA
investigator that during the CDAD
clinical trial he was present when his
co-conspirator, the Principal
Investigator, had obtained all the
informed consents from the trial
subjects. Mr. Montalvo Villa also told
the regulatory investigator that copies of
the informed consent were given to the
subjects and that he was the most
responsible person at AMB.
Mr. Montalvo Villa received
$100,634.84 in proceeds for the CDAD
clinical trial. AMB received over
$277,000 for the CDAD clinical trial.
FDA sent Mr. Montalvo Villa, by
certified mail, on August 12, 2024, a
notice proposing to permanently debar
him from providing services in any
capacity to a person that has an
approved or pending drug product
application. The proposal was based on
a finding, under section 306(a)(2)(A) of
the FD&C Act, that Mr. Montalvo Villa
was convicted of a felony under Federal
law for conduct relating to the
development or approval, including the
process of development or approval, of
any drug product. The proposal
VerDate Sep<11>2014
18:39 Nov 19, 2024
Jkt 265001
informed Mr. Montalvo Villa of the
proposed debarment and offered him an
opportunity to request a hearing,
providing him 30 days from the date of
receipt of the letter in which to file the
request, and advised him that failure to
request a hearing constituted a waiver of
the opportunity for a hearing and of any
contentions concerning this action. Mr.
Montalvo Villa received the proposal
and notice of opportunity for a hearing
on August 20, 2024. Mr. Montalvo Villa
failed to request a hearing within the
timeframe prescribed by regulation and
has, therefore, waived his opportunity
for a hearing and waived any
contentions concerning his debarment
(21 CFR part 12).
II. Findings and Order
Therefore, the Division of Field
Enforcement Director, Office of
Inspections and Investigations, under
section 306(a)(2)(A) of the FD&C Act,
under authority delegated to the
Division of Field Enforcement Director,
finds that Mr. Miguel Angel Montalvo
Villa has been convicted of a felony
under Federal law for conduct relating
to the development or approval,
including the process of development or
approval, of any drug product.
As a result of the foregoing finding,
Mr. Montalvo Villa is permanently
debarred from providing services in any
capacity to a person with an approved
or pending drug product application,
effective (see DATES) (see sections
306(a)(2)(A) and 306(c)(2)(A)(ii) of the
FD&C Act). Any person with an
approved or pending drug product
application who knowingly employs or
retains as a consultant or contractor, or
otherwise uses in any capacity the
services of Mr. Montalvo Villa during
his debarment, will be subject to civil
money penalties (section 307(a)(6) of the
FD&C Act (21 U.S.C. 335b(a)(6))). If Mr.
Montalvo Villa provides services in any
capacity to a person with an approved
or pending drug product application
during his period of debarment, he will
be subject to civil money penalties
(section 307(a)(7) of the FD&C Act). In
addition, FDA will not accept or review
any abbreviated new drug application
from Mr. Montalvo Villa during his
period of debarment, other than in
connection with an audit under section
306 of the FD&C Act (section
306(c)(1)(B) of the FD&C Act). Note that,
for purposes of sections 306 and 307 of
the FD&C Act, a ‘‘drug product’’ is
defined as a ‘‘drug subject to regulation
under section 505, 512, or 802 of the
FD&C Act (21 U.S.C. 355, 360b, 382) or
under section 351 of the Public Health
Service Act (42 U.S.C. 262)’’ (section
PO 00000
Frm 00089
Fmt 4703
Sfmt 4703
201(dd) of the FD&C Act (21 U.S.C.
321(dd))).
Dated: November 7, 2024.
Kimberlee Trzeciak,
Deputy Commissioner for Policy, Legislation,
and International Affairs.
[FR Doc. 2024–27093 Filed 11–19–24; 8:45 am]
BILLING CODE 4164–01–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Food and Drug Administration
[Docket No. FDA–2022–N–0150]
Revocation of Two Authorizations of
Emergency Use of In Vitro Diagnostic
Devices for Detection and/or Diagnosis
of COVID–19; Availability
AGENCY:
Food and Drug Administration,
HHS.
ACTION:
Notice.
The Food and Drug
Administration (FDA) is announcing the
revocation of the Emergency Use
Authorizations (EUAs) (the
Authorizations) issued to Cue Health,
Inc., for the Cue COVID–19 Test, and
Cue COVID–19 Test for Home and Over
The Counter (OTC) Use. FDA revoked
the Authorizations under the Federal
Food, Drug, and Cosmetic Act (FD&C
Act) as requested by the Authorization
holder. The revocations, which include
an explanation of the reasons for each
revocation, are reprinted at the end of
this document.
DATES: The revocation of the
Authorizations for the Cue Health, Inc.’s
Cue COVID–19 Test, and Cue COVID–19
Test for Home and Over The Counter
(OTC) Use are effective as of October 9,
2024.
ADDRESSES: Submit written requests for
a single copy of the revocations to the
Office of Policy, Center for Devices and
Radiological Health, Food and Drug
Administration, 10903 New Hampshire
Ave., Bldg. 66, Rm. 5431, Silver Spring,
MD 20993–0002. Send one selfaddressed adhesive label to assist that
office in processing your request or
include a fax number to which the
revocations may be sent. See the
SUPPLEMENTARY INFORMATION section for
electronic access to the revocations.
FOR FURTHER INFORMATION CONTACT: Kim
Sapsford-Medintz, Office of Product
Evaluation and Quality, Center for
Devices and Radiological Health, Food
and Drug Administration, 10903 New
Hampshire Ave., Bldg. 66, Rm. 3216,
Silver Spring, MD 20993–0002, 301–
796–0311 (this is not a toll-free
number).
SUMMARY:
E:\FR\FM\20NON1.SGM
20NON1
Federal Register / Vol. 89, No. 224 / Wednesday, November 20, 2024 / Notices
SUPPLEMENTARY INFORMATION:
I. Background
khammond on DSK9W7S144PROD with NOTICES
Section 564 of the FD&C Act (21
U.S.C. 360bbb–3) as amended by the
Project BioShield Act of 2004 (Pub. L.
108–276) and the Pandemic and AllHazards Preparedness Reauthorization
Act of 2013 (Pub. L. 113–5) allows FDA
to strengthen the public health
protections against biological, chemical,
radiological, or nuclear agent or agents.
Among other things, section 564 of the
FD&C Act allows FDA to authorize the
use of an unapproved medical product
or an unapproved use of an approved
medical product in certain situations.
On June 10, 2020, FDA issued the
Authorization to Cue Health, Inc., for
the Cue COVID–19 Test, subject to the
terms of the Authorization. Notice of the
issuance of this Authorization was
published in the Federal Register on
November 20, 2020 (85 FR 74346), as
required by section 564(h)(1) of the
FD&C Act.
On March 5, 2021, FDA issued the
Authorization to Cue Health, Inc., for
the Cue COVID–19 Test for Home and
Over The Counter (OTC) Use, subject to
the terms of the Authorization. Notice of
the issuance of this Authorization was
published in the Federal Register on
VerDate Sep<11>2014
18:39 Nov 19, 2024
Jkt 265001
July 23, 2021 (86 FR 39040), as required
by section 564(h)(1) of the FD&C Act.
Subsequent updates to the
Authorizations were made available on
FDA’s website. The authorization of a
device for emergency use under section
564 of the FD&C Act may, pursuant to
section 564(g)(2) of the FD&C Act, be
revoked when the criteria under section
564(c) of the FD&C Act for issuance of
such authorization are no longer met
(section 564(g)(2)(B) of the FD&C Act),
or other circumstances make such
revocation appropriate to protect the
public health or safety (section
564(g)(2)(C) of the FD&C Act).
II. Authorizations Revocation Requests
In a request received by FDA on
September 9, 2024, Cue Health, Inc.,
requested the revocation of, and on
October 9, 2024, FDA revoked, the
Authorization for the Cue Health, Inc.’s
Cue COVID–19 Test. Because Cue
Health, Inc., notified FDA that they
ceased manufacturing, shipping, and
distributing the Cue COVID–19 Test and
requested FDA revoke the Cue COVID–
19 Test, FDA has determined that it is
appropriate to protect the public health
or safety to revoke this Authorization.
In a request received by FDA on
September 9, 2024, Cue Health, Inc.,
requested the revocation of, and on
PO 00000
Frm 00090
Fmt 4703
Sfmt 4703
91761
October 9, 2024, FDA revoked, the
Authorization for Cue Health, Inc.’s Cue
COVID–19 Test for Home and Over The
Counter (OTC) Use. Because Cue Health,
Inc., notified FDA that they have ceased
manufacturing, shipping, and
distributing the Cue COVID–19 Test for
Home and Over The Counter (OTC) Use
and requested FDA revoke the Cue
COVID–19 Test for Home and Over The
Counter (OTC) Use, FDA has
determined that it is appropriate to
protect the public health or safety to
revoke this Authorization.
III. Electronic Access
An electronic version of this
document and the full text of the
revocations are available on the internet
at https://www.regulations.gov/.
IV. The Revocations
Having concluded that the criteria for
revocation of the Authorizations under
section 564(g)(2)(C) of the FD&C Act are
met, FDA has revoked the EUAs of Cue
Health, Inc.’s Cue COVID–19 Test, and
Cue COVID–19 Test for Home and Over
The Counter (OTC) Use. The revocations
in their entirety follow and provide an
explanation of the reasons for
revocation, as required by section
564(h)(1) of the FD&C Act.
BILLING CODE 4164–01–P
E:\FR\FM\20NON1.SGM
20NON1
VerDate Sep<11>2014
Federal Register / Vol. 89, No. 224 / Wednesday, November 20, 2024 / Notices
18:39 Nov 19, 2024
Jkt 265001
PO 00000
Frm 00091
Fmt 4703
Sfmt 4725
E:\FR\FM\20NON1.SGM
20NON1
EN20NO24.071
khammond on DSK9W7S144PROD with NOTICES
91762
Federal Register / Vol. 89, No. 224 / Wednesday, November 20, 2024 / Notices
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Food and Drug Administration
[FR Doc. 2024–27094 Filed 11–19–24; 8:45 am]
[Docket No. FDA–2007–D–0369]
khammond on DSK9W7S144PROD with NOTICES
BILLING CODE 4164–01–C
Product-Specific Guidances; Draft and
Revised Draft Guidances for Industry;
Availability
AGENCY:
Food and Drug Administration,
HHS.
ACTION:
VerDate Sep<11>2014
18:39 Nov 19, 2024
Jkt 265001
PO 00000
Notice of availability.
Frm 00092
Fmt 4703
Sfmt 4703
The Food and Drug
Administration (FDA or Agency) is
announcing the availability of
additional draft and revised draft
product-specific guidances. The draft
guidances provide product-specific
recommendations on, among other
things, the design of bioequivalence
(BE) studies to support abbreviated new
drug applications (ANDAs). In the
Federal Register of June 11, 2010, FDA
announced the availability of a guidance
for industry entitled ‘‘Bioequivalence
Recommendations for Specific
SUMMARY:
E:\FR\FM\20NON1.SGM
20NON1
EN20NO24.072
Dated: November 14, 2024.
Kimberlee Trzeciak,
Deputy Commissioner for Policy, Legislation,
and International Affairs.
91763
Agencies
[Federal Register Volume 89, Number 224 (Wednesday, November 20, 2024)]
[Notices]
[Pages 91760-91763]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2024-27094]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
Food and Drug Administration
[Docket No. FDA-2022-N-0150]
Revocation of Two Authorizations of Emergency Use of In Vitro
Diagnostic Devices for Detection and/or Diagnosis of COVID-19;
Availability
AGENCY: Food and Drug Administration, HHS.
ACTION: Notice.
-----------------------------------------------------------------------
SUMMARY: The Food and Drug Administration (FDA) is announcing the
revocation of the Emergency Use Authorizations (EUAs) (the
Authorizations) issued to Cue Health, Inc., for the Cue COVID-19 Test,
and Cue COVID-19 Test for Home and Over The Counter (OTC) Use. FDA
revoked the Authorizations under the Federal Food, Drug, and Cosmetic
Act (FD&C Act) as requested by the Authorization holder. The
revocations, which include an explanation of the reasons for each
revocation, are reprinted at the end of this document.
DATES: The revocation of the Authorizations for the Cue Health, Inc.'s
Cue COVID-19 Test, and Cue COVID-19 Test for Home and Over The Counter
(OTC) Use are effective as of October 9, 2024.
ADDRESSES: Submit written requests for a single copy of the revocations
to the Office of Policy, Center for Devices and Radiological Health,
Food and Drug Administration, 10903 New Hampshire Ave., Bldg. 66, Rm.
5431, Silver Spring, MD 20993-0002. Send one self-addressed adhesive
label to assist that office in processing your request or include a fax
number to which the revocations may be sent. See the SUPPLEMENTARY
INFORMATION section for electronic access to the revocations.
FOR FURTHER INFORMATION CONTACT: Kim Sapsford-Medintz, Office of
Product Evaluation and Quality, Center for Devices and Radiological
Health, Food and Drug Administration, 10903 New Hampshire Ave., Bldg.
66, Rm. 3216, Silver Spring, MD 20993-0002, 301-796-0311 (this is not a
toll-free number).
[[Page 91761]]
SUPPLEMENTARY INFORMATION:
I. Background
Section 564 of the FD&C Act (21 U.S.C. 360bbb-3) as amended by the
Project BioShield Act of 2004 (Pub. L. 108-276) and the Pandemic and
All-Hazards Preparedness Reauthorization Act of 2013 (Pub. L. 113-5)
allows FDA to strengthen the public health protections against
biological, chemical, radiological, or nuclear agent or agents. Among
other things, section 564 of the FD&C Act allows FDA to authorize the
use of an unapproved medical product or an unapproved use of an
approved medical product in certain situations.
On June 10, 2020, FDA issued the Authorization to Cue Health, Inc.,
for the Cue COVID-19 Test, subject to the terms of the Authorization.
Notice of the issuance of this Authorization was published in the
Federal Register on November 20, 2020 (85 FR 74346), as required by
section 564(h)(1) of the FD&C Act.
On March 5, 2021, FDA issued the Authorization to Cue Health, Inc.,
for the Cue COVID-19 Test for Home and Over The Counter (OTC) Use,
subject to the terms of the Authorization. Notice of the issuance of
this Authorization was published in the Federal Register on July 23,
2021 (86 FR 39040), as required by section 564(h)(1) of the FD&C Act.
Subsequent updates to the Authorizations were made available on
FDA's website. The authorization of a device for emergency use under
section 564 of the FD&C Act may, pursuant to section 564(g)(2) of the
FD&C Act, be revoked when the criteria under section 564(c) of the FD&C
Act for issuance of such authorization are no longer met (section
564(g)(2)(B) of the FD&C Act), or other circumstances make such
revocation appropriate to protect the public health or safety (section
564(g)(2)(C) of the FD&C Act).
II. Authorizations Revocation Requests
In a request received by FDA on September 9, 2024, Cue Health,
Inc., requested the revocation of, and on October 9, 2024, FDA revoked,
the Authorization for the Cue Health, Inc.'s Cue COVID-19 Test. Because
Cue Health, Inc., notified FDA that they ceased manufacturing,
shipping, and distributing the Cue COVID-19 Test and requested FDA
revoke the Cue COVID-19 Test, FDA has determined that it is appropriate
to protect the public health or safety to revoke this Authorization.
In a request received by FDA on September 9, 2024, Cue Health,
Inc., requested the revocation of, and on October 9, 2024, FDA revoked,
the Authorization for Cue Health, Inc.'s Cue COVID-19 Test for Home and
Over The Counter (OTC) Use. Because Cue Health, Inc., notified FDA that
they have ceased manufacturing, shipping, and distributing the Cue
COVID-19 Test for Home and Over The Counter (OTC) Use and requested FDA
revoke the Cue COVID-19 Test for Home and Over The Counter (OTC) Use,
FDA has determined that it is appropriate to protect the public health
or safety to revoke this Authorization.
III. Electronic Access
An electronic version of this document and the full text of the
revocations are available on the internet at https://www.regulations.gov/.
IV. The Revocations
Having concluded that the criteria for revocation of the
Authorizations under section 564(g)(2)(C) of the FD&C Act are met, FDA
has revoked the EUAs of Cue Health, Inc.'s Cue COVID-19 Test, and Cue
COVID-19 Test for Home and Over The Counter (OTC) Use. The revocations
in their entirety follow and provide an explanation of the reasons for
revocation, as required by section 564(h)(1) of the FD&C Act.
BILLING CODE 4164-01-P
[[Page 91762]]
[GRAPHIC] [TIFF OMITTED] TN20NO24.071
[[Page 91763]]
[GRAPHIC] [TIFF OMITTED] TN20NO24.072
Dated: November 14, 2024.
Kimberlee Trzeciak,
Deputy Commissioner for Policy, Legislation, and International Affairs.
[FR Doc. 2024-27094 Filed 11-19-24; 8:45 am]
BILLING CODE 4164-01-C